Physician profile
Behnoud Beroukhim
NPI 1639477136
$13,309.27
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,522 · 2020: $2,605 · 2021: $1,650 · 2022: $179 · 2023: $240 · 2024: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $248 · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $247.93 |
| Education | $105.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $12,105.68 | 2019-2023 | Veltassa |
| Otsuka America Pharmaceutical, INC. | $224.19 | 2019-2023 | Jynarque |
| Amgen INC. | $201.12 | 2019-2022 | |
| Glaxosmithkline, LLC. | $176.40 | 2022-2024 | Jesduvroq, Benlysta |
| Alexion Pharmaceuticals, INC. | $98.99 | 2019 | |
| Opko Pharmaceuticals, LLC | $79.56 | 2019 | |
| Mallinckrodt Hospital Products INC. | $79.00 | 2023 | Acthar |
| Abbvie INC. | $71.48 | 2021 | |
| Daiichi Sankyo INC. | $67.25 | 2019 | |
| Horizon Therapeutics Plc | $56.55 | 2019-2021 | |
| Fresenius USA Marketing, INC. | $42.18 | 2019-2024 | Velphoro |
| Astrazeneca Pharmaceuticals LP | $35.71 | 2019-2023 | Lokelma |
| Aurinia Pharma U.S., INC. | $27.69 | 2023 | Lupkynis |
| Scpharmaceuticals INC. | $22.47 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Behnoud Beroukhim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.